Overview

Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.
Phase:
Phase 3
Details
Lead Sponsor:
Mundipharma Research Limited
Treatments:
Fluticasone
Formoterol Fumarate
Xhance